Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Helios who wrote (2412)	3/28/2000 1:14:00 AM
From: DanZ	Read Replies (1) \| Respond to of 5582

Helios, Zicam sold well domestically this cold season relative to the cough and cold category. It was in the top 2% of sales in December and January, but the cold season ended early due to warm weather all over the United States. Based on my research, sales of all brands of cough and cold products peaked in January so I don't think there is an issue with Zicam in particular. Retailers have told Gum Tech that they are very pleased with sales of Zicam. What does chewing tobacco have to do with nicotine gum? There are two distinct markets for nicotine gum: smoking cessation (competes with Nicorette) and nicotine delivery for people that want a safer delivery system for nicotine than smoking. It is my belief that the Gum Tech/Swedish Match joint venture will go after both markets. The market for smoking cessation products was valued at about $450 million last year, and approximately $46 billion was spent on tobacco products in the US alone in 1998. The smoking cessation market is expected to grow to $1.5 billion within six years, and I believe that Gum Tech/Swedish Match will get a good part of that market. I agree with your comment that account receivables increased relative to sales in 1999, but I think that there is a reasonable explanation for it. One way to look at account receivables is to divide them by the trailing twelve months sales and compare the ratio to the same period in the prior years to remove any seasonality. This is called the torpedo ratio, and one can also calcuate it for inventory. If you calculate this, you will find that prior to the launch of Zicam, Gum Tech's torpedo ratio for receivables was fairly constant starting in Q3 1997. The most likely reason for the increase in 1999 relative to 1998 is that Gum Tech gave retailers more favorable collection periods during the launch of Zicam. I would ignore the data in Q1 and Q2 1997 because this was before the new management team came in and changed the company's strategy from building their own brand names to focusing on contract manufacturing. This was a significant change in the business plan, so I don't think that it is unusual for the collection period to change. As long as the ratio declines towards 20% to 25% next year, I don't think it is anything to be concerned about. Here is the data: 1997 1998 1999 Q1: 13.7% 20.1% 30.6% Q2: 13.7% 20.2% 25.3% Q3: 24.6% 25.5% 33.9% Q4: 28.6% 27.7% Regarding your comment about interest expense, Gum Tech recently redeemed Citadel's debt and paid off all their other remaining debt. They will have zero interest expense in the first quarter 2000 and every quarter going forward unless they borrow again. They also received several million dollars from the exercise of options and warrants in the last few months. I don't have the figures handy, but I would guess that they received at least $5 million in cash. They made a profit last quarter (~$1 million), and I definitely disagree with your comment that they could run out of money early next year. Their Q4 99 cash flow statement, which should be out by March 31, will look much different than previous quarters. Regards, Dan

To: Helios who wrote (2412)	3/28/2000 6:53:00 AM
From: Hank	Respond to of 5582

Like I said, good luck battling these guys. Dan will literally bore you into a coma by automatically contradicting any negative comment you have about GUMM using seemingly impressive but totally hypothetical or irrelevent numbers. Mike will just do what he does best and be totally obnoxious at every available opportunity. He tried to be intelligent once but it nearly gave him an aneurysm, so now he just grunts and farts. With the cold season over and no new products on the shelves, GUMM's stock price will continue to decay along with it's "earnings" for the remainder of the year.

To: Helios who wrote (2412)	3/28/2000 5:42:00 PM
From: Mike M	Read Replies (2) \| Respond to of 5582

In their income statements I see ballooning receivables without an increase in sales, increasing interest expenses (the creditors may end up owning this company before it makes a dime), and a cash burn rate of about a million a quarter, it should be gone by early year if they can't make some money. That is the problem of analyzing with historical data. There are no creditors. There is no cash burn since 3d qtr 99. $5M in the bank and another $3M at Gel Tech(60% owned by GUMM).... Sales this quarter will probably result in break even bottom line and positive cash flow. A product launch with a very large consumer staples company is anticipated next quarter. Until you ask the CEO why he sold some of his shares you are shooting in the dark on that count. You can follow Hank's advice if you want but how would you know in which asylum to look for him when you want to kick his silly butt after the short goes sour?